Home » Topics » BioWorld Science

BioWorld Science
RSS

Japanese approval for Blincyto for relapsed or refractory B-cell ALL

Sep. 25, 2018

Phase III trial of Soliris in neuromyelitis optica spectrum disorder meets primary endpoint

Sep. 25, 2018

First patient enrolled in phase I study of THR-687 for the treatment of diabetic macular edema

Sep. 25, 2018

Pharmaxis synthesizes new LOX inhibitors

Sep. 25, 2018

Japanese approval for Jivi for hemophilia A

Sep. 25, 2018

FDA grants approval for Copiktra for CLL/SLL, accelerated approval in follicular lymphoma

Sep. 25, 2018

Phase IIa trial of EPI-589 in ALS shows improvement in CSF and plasma-based biomarkers

Sep. 25, 2018

Imfinzi approved in E.U. for locally advanced, unresectable NSCLC

Sep. 25, 2018

FDA lifts partial clinical hold on tazemetostat trials

Sep. 25, 2018

New PKU mouse model developed

Sep. 25, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 17, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...